Published 3 days ago • loading... • Updated 3 days agoShow Less IconRegeneron Pharmaceuticals (NASDAQ:REGN) Given New $1,075.00 Price Target at Barclays Summary by MarketBeatBarclays increased their price objective on Regeneron Pharmaceuticals from $917.00 to $1,075.00 and gave the stock an "overweight" rating in a report on Tuesday.Share menu1 Articles1 ArticlesAllLeftCenter1RightSearch IconSort IconMarketBeatCenterFactualityOwnershipRegeneron Pharmaceuticals (NASDAQ:REGN) Given New $1,075.00 Price Target at BarclaysBarclays increased their price objective on Regeneron Pharmaceuticals from $917.00 to $1,075.00 and gave the stock an "overweight" rating in a report on Tuesday.3 days ago·Sioux Falls, United StatesRead Full ArticleThink freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribeBlindspot Title And LogoStories disproportionately reported by the Left or the RightSee More BlindspotsCoverage DetailsTotal News Sources1Leaning Left0Leaning Right0Center1Last Updated3 days agoBias Distribution100% CenterBias Distribution Too Big Arrow IconToo Big Arrow IconCaret Up Icon100% of the sources are Center100% CenterC 100%Factuality Info IconTo view factuality data please Upgrade to PremiumOwnership Info IconTo view ownership data please Upgrade to VantageMarketBeat broke the news in Sioux Falls, United States 3 days ago on Tuesday, November 17, 2026.Too Big Arrow IconCaret Down IconSources are mostly out of (0)Similar News TopicsTarrytown Plus IconShow AllBlindspot Title And LogoStories disproportionately reported by the Left or the RightSee More BlindspotsSimilar News TopicsTarrytown Plus IconShow All